![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Phase III study showed Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80% by Roche
Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of...
Clinical Trials
QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer compound
 QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration...
Clinical Trials
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration...
Clinical Trials
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Abbott Park, Illinois-Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic...
Clinical Trials
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development
Novartis announced that the clinical trial program for the investigational cancer treatment ASA404 (vadimezan) will be discontinued and resources will be reallocated to other...
Clinical Trials
Genentech announced the result of Phase II clinical trail of RG7204
Genentech, Inc., a member of the Roche Group announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed...
Clinical Trials
Sanofi Pasteur’s Dengue Vaccine in Final Stage of Clinical Development
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur’s dengue vaccine,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read